Gastrointestinal Cancer | Specialty

Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages

February 28th 2019

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

Headway Made in GI Cancer Treatment, But Progress Needed

February 28th 2019

Brandon Smaglo, MD, highlights investigational treatment approaches for patients with gastric cancer and calls for further research in the adjuvant setting to move the needle forward.

Frontline Olaparib Maintenance Improves PFS in BRCA+ Pancreatic Cancer

February 26th 2019

Frontline maintenance therapy with olaparib significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial.

FOLFIRINOX Should Remain Adjuvant Standard for Resectable Pancreatic Cancer

February 26th 2019

Matthew H.G. Katz, MD, FACS, highlights pivotal trials in pancreatic cancer and how these data are shifting the treatment paradigm for these patients.

Dr. Overman Discusses ReDOS Study in mCRC

February 26th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Dr. Weinberg Discusses the Use of FOLFIRINOX in Older Patients With Metastatic Pancreatic Cancer

February 26th 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the use of FOLFIRINOX in older patients with metastatic pancreatic cancer.

Dr. Smaglo Discusses the FDA Approval of TAS-102 for Gastric/GEJ Cancer

February 26th 2019

Brandon G. Smaglo, MD, FACP, assistant professor of internal medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the FDA approval of TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Lutathera Leads Therapeutic Advances in NETs

February 26th 2019

Daniel M. Halperin, MD, sheds light on the latest research in neuroendocrine tumors.

Molecular Testing Needed to Inform CRC Treatment Decisions

February 25th 2019

Michael Overman, MD, highlights data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discusses where research efforts should be focused to improve the treatment of patients with colorectal cancer.

FDA Approves TAS-102 for Gastric/GEJ Cancer

February 25th 2019

The FDA has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Dr. Chung on the COMPASS Trial in Pancreatic Cancer

February 23rd 2019

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.

Dr. Eng on Recognizing Tumor Sidedness in mCRC

February 23rd 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Eng Highlights Important Treatment Considerations in mCRC

February 22nd 2019

Cathy Eng, MD, FACP, discusses the current treatment options available for patients with metastatic colorectal cancer and highlights recent data in the space.

Dr. Lee on the Benefit of Cytoreductive Surgery in Metastatic Colorectal Cancer

February 21st 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).

Pembrolizumab Misses Primary Endpoints in HCC Trial

February 21st 2019

The combination of pembrolizumab plus best supportive care for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy did not improve progression-free or overall survival compared with placebo plus best supportive care alone, missing the coprimary endpoints of the KEYNOTE-240 trial.

Pancreatic Cancer: Unmet Needs and Future Directions

February 20th 2019

Nanoliposomal Irinotecan in Pancreatic Cancer: Managing AEs

February 20th 2019

Nanoliposomal Irinotecan's Role in Pancreatic Cancer

February 20th 2019

Pancreatic Cancer: Addressing AEs and Optimizing Care

February 20th 2019

Educating Patients With Pancreatic Cancer on Adverse Events

February 20th 2019